Novartis announced  that the US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In